24/7 Market News Snapshot 24 June, 2025 – OS Therapies Incorporated (NYSE:OSTX)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NYSE:OSTX) are discussed in this article.
OS Therapies Incorporated (NYSE-A: OSTX) is currently witnessing a surge in its stock performance, trading at $1.882 in pre-market sessions, reflecting an impressive increase of 10.71% from the previous closing price of $1.700. This uptick is underscored by a trading volume of 604.18K shares, indicative of heightened investor interest and strong buying momentum, which suggests the potential for continued upward price movement. Key technical levels for OSTX include support at $1.700 and resistance at approximately $2.00, with moving averages further reinforcing the positive sentiment surrounding the stock.

In a strategic development, OS Therapies has announced an inducement and exchange offer targeting holders of its existing warrants from a past PIPE financing transaction. This initiative allows these investors to exchange their current five-year warrants, which have an exercise price of $1.12, for new warrants with an exercise price of $3.00 per share. This exchange not only aims to strengthen the Company’s financial position but also seeks to enhance shareholder engagement. By participating in this program, warrant holders could help generate an estimated gross cash inflow of around $8 million, significantly extending the Company’s financial runway into the second half of 2026. The early reception of $1.76 million from Old Warrant exercise proceeds illustrates robust investor involvement.

Additionally, the new warrants will feature a forced exercise provision that mandates holders to exercise the new warrants if the Company’s stock price hits or exceeds $9.00 for a consecutive period. The net proceeds from this transaction are slated to support regulatory initiatives and pre-commercial activities for OST-HER2, its primary product candidate aimed at securing marketing authorization for the prevention and delay of recurrent lung metastatic osteosarcoma. OS Therapies also plans to provide updates in advance of the MIB Factor meeting, including new data from its Phase 2b clinical trial and progress on its Biologics Licensing Application (BLA) submission to the FDA, scheduled for the third quarter of 2025. The Company remains dedicated to pioneering innovations in oncology and values the continued support of its stakeholders.

Related news for (OSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.